Akcije

Archive of Oncology
kako citirati ovaj članak
podeli ovaj članak

Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 2 od 3  
Back povratak na rezultate
2018, vol. 24, br. 2, str. 20-23
Expression of epidermal growth factor receptor in advance stage nonkeratinizing nasopharyngeal carcinoma in West Sumatra, Indonesia
(naslov ne postoji na srpskom)
aAndalas University, Faculty of Medicine, Dr. M. Djamil General Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Padang, Indonesia
bAndalas University, Faculty of Medicine, Dr. M. Djamil General Hospital, Department of Pathology, Padang, Indonesia
cAndalas University, Faculty of Medicine, Department of Public Health, Padang, Indonesia

e-adresasukrirahman@fk.unand.ac.id
Ključne reči: nonkeratinizing; nasopharyngeal carcinoma; epidermal growth factor receptor
Sažetak
(ne postoji na srpskom)
Introduction: Nasopharyngeal carcinoma is a head and neck cancer with a unique geographic distribution. Indonesia is one of the countries with an intermediate incidence of nasopharyngeal carcinoma where 13,000 new cases are found every year or 6.2 cases/100,000 in population per year. The subcellular mechanism of the nasopharyngeal carcinoma has not been clearly confirmed, but in several studies overexpression of the epidermal growth factor receptor was found. Based on histopathological classification, nonkeratinizing subtypes consisting of differentiated (WHO II) and undifferentiated (WHO III) are the most frequent types in endemic areas, whereas in non-endemic areas the majority of cases are keratinizing subtype (WHO I). The objective of this study was to evaluate the expression of epidermal growth factor receptor in advanced stage nonkeratinizing nasopharyngeal carcinoma as well as to evaluate difference in the expression between differentiated nonkeratinizing (WHO II) and undifferentiated (WHO III) nasopharyngeal carcinoma that may affect the anti-epidermal growth factor receptor therapy for nasopharyngeal carcinoma. Methods: Biopsies from 34 advance stage (stage III and stage IV) nonkeratinizing nasopharyngeal carcinoma consisting of 17 differentiated nonkeratinizing and 17 undifferentiated carcinomas were included in the study. Expression of epidermal growth factor receptor in tumor tissues was investigated by immunohistochemistry (IHC). Results: Our results demonstrated that epidermal growth factor receptor was expressed in 23 out of 34 subjects (67.65%). Expression in differentiated nonkeratinizing nasopharyngeal carcinoma was 76.47% (13 out of 17), and it was higher than in undifferentiated carcinoma (58.82%), but there was no statistically significant difference between the two histopathological subtypes (p=0.465). Conclusions: The epidermal growth factor receptor was expressed in most cases of advance stage nonkeratinizing nasopharyngeal carcinoma, and there was no difference in the expression between differentiated nonkeratinizing (WHO II) and undifferentiated nonkeratinizing nasopharyngeal carcinoma (WHO III).
Reference
Brennan, B. (2006) Nasopharyngeal carcinoma. Orphanet Journal of Rare Diseases, 1(1): 23
Chan, J.K.C., Bray, F., Mccarron, P., Foo, W. (2005) Nasopharyngeal carcinoma. u: Barnes L., Eveson J.W., Reichart P., Sidrasky D. [ur.] WHO classification of tumors: Pathology and genetics head and neck tumors, Lyon, p. 85-97
Chang, E.T., Adami, H.O. (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer epidemiology, biomarkers & prevention, 15(10): 1765-77
Chen, X., Yeung, T.K., Wang, Z. (2000) Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3. Biochemical and Biophysical Research Communications, 277(3): 757-763
Chua, D.T., Nicholls, J.M., Sham, J.S., Au, G.K. (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. International Journal of Radiation Oncology*Biology*Physics, 59(1): 11-20
Ekburaranawat, W., Ekspanyaskul, C., Brennan, P., Kanka, C., Tepsuwan, K., Temisyatith, S., i dr. (2010) Evaluation of Non-Viral Risk Factors for Nasopharyngeal Carcinoma in Thailand: results from a Case-control Study. Asian Pacific J Cancer Prev, 11: 929-32
Fujii, M., Yamashita, T., Ishiguro, R., Tashiro, M., Kameyama, K. (2002) Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx, 29(2): 175-181
Guo, X., Johnson, R.C., Deng, H., Liao, J., Guan, L., Nelson, G.W., Tang, M., Zheng, Y., The, G., Brien, S.O.J., Winkler, C.A., Zeng, Y. (2009) Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. International Journal of Cancer, 124(12): 2942-7
Huang, T.L., Li, C.F., Huang, H.Y., Fang, F.M. (2010) Correlations between Expression of Epidermal Growth Factor Receptor (EGFR), Phosphorylated EGFR, Cyclooxygenase-2 and Clinicopathological Variables and Treatment Outcomes in Nasopharyngeal Carcinomas. Chang Gung Med J, 33: 619-26
Huang, Y., Zhang, B., Ma, N., Murata, M., Tang, A., Huang, G. (2011) Nitrative and oxidative DNA damage as potential survival biomarkers for nasopharyngeal carcinoma. Medical Oncology, 28(1): 377-384
Lutzky, V.P., Moss, D.J., Chin, D., Coman, W.B., Parsons, P.G., Boyle, G.M. (2008) Biomarkers for Cancers of the Head and Neck. Clin Med ENT, 1: 5-15
Ma, J., Cao, S. (2010) The Epidemiology of Nasopharyngeal Carcinoma. Berlin, Heidelberg: Springer Nature, str. 1-7
Newby, J.C., Johnston, S.R., Smith, I.E., Dowsett, M. (1997) Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res, 3(9): 1643-51
Putti, T.C., To, K.F., Hsu, H.C., Chan, A.T.C., Lai, G.M., Tse, G., Lee, Y.S., Whang-Peng, J., Millward, M., Lin, L., Lin, X., Lee, C.S. (2002) Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology, 41(2): 144-151
Roezin, A. (2002) Faktor Risiko pada Karsinoma Nasofaring. Maj patologi, Indonesia, 11(4); 42-45
Sartor, C.I. (2000) Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family. Semin Oncol, 27(suppl 11): 15-20
Scaltriti, M., Baselga, J. (2006) The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy. Clinical Cancer Research, 12(18): 5268-5272
Thompson, L.D.R. (2006) Malignant Neoplasma of the nasal cavity, paranasal sinuses and nasopharynx. u: Thompson LDR [ur.] Head and Neck Pathology, Philadelphia: Elsevier, p. 170-3
Tulalamba, W., Janvilisri, T. (2012) Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers. International Journal of Cell Biology, 2012: 1-10
Turkoz, F.P., Celenkoglu, G., Dogu, G.G., Kalender, M.E., Coskun, U., Alkis, N., i dr. (2011) Risk Factors of Nasopharyngeal Carcinoma in Turkey- an Epidemiological Survey of the Anatolian Society of Medical Oncology. Asian Pacific J Cancer Prevention, 12: 3017-21
Wei, W.I. (2006) Nasopharyngeal Cancer. u: Bailey , Johnson , Byron, Newlands , Jonas T., Shawn D. [ur.] Head and Neck Surgery Otolaryngology, Lippincot Williams and Wilkins, p. 1658-68, Fourt Edition
Yarden, Y., Sliwkowski, M.X. (2001) Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2): 127-137
Zeng, M., Zeng, Y. (2010) Pathogenesis and Etiology of Nasopharyngeal Carcinoma. Berlin, Heidelberg: Springer Nature, str. 9-25
 

O članku

jezik rada: engleski
vrsta rada: članak
DOI: 10.2298/AOO180401005R
objavljen u SCIndeksu: 25.10.2018.
metod recenzije: jednostruko anoniman
Creative Commons License 4.0

Povezani članci

Nema povezanih članaka